Bulent Urman
Bulent Urman has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Baris Ata
ART Fertility Clinics, Dubai, United Arab Emirates; Department of Obstetrics and Gynecology, Koc University School of Medicine, Istanbul, Turkiye
5 shared publications - Ahmet Demir
Clinic of Obstetrics and Gynecology, University of Heathy Sciences Türkiye, İzmir Tepecik Training and Research Hospital, İzmir, Türkiye
2 shared publications Basak Balaban
American Hospital, Istanbul, Turkey
2 shared publications- Başak Balaban
Clinic of Assisted Reproduction Unit, Vehbi Koç Foundation American Hospital, İstanbul, Türkiye
2 shared publications - Can Benlioglu
Research Center for Translational Medicine, Koç University , Istanbul
2 shared publications - Elif Ergin
Bursa Eurofertil IVF Center Bursa Turkey
2 shared publications
Latest Publications
- Open Access
- 10 June 2025
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 26 (2) , 109-115
In-depth analysis of the demographic landscape and clinical outcomes of assisted reproductive technologies in Türkiye: a comprehensive survey for the years 2020 and 2021
To investigate patient characteristics and outcomes of assisted reproductive technology (ART) cycles conducted in Türkiye during the coronavirus disease-2019 (COVID-19) pandemic (2020-2021). ART centers in Türkiye were invited to participate in this survey. The questionnaire focused on patient demographics and performance outcomes and was sent to center directors via anonymous Qualtrics™ links. The survey was sent to 167 centers and data were collected from 15 centers in 2020 and 24 centers in 2021. The clinical pregnancy rate from intrauterine insemination (IUI) procedures remained similar, with 15.1% in 2020 (1,245 IUI cycles) and 14.5% in 2021 (2,023 IUI cycles), while successful delivery rates were 12.5% and 11.5%, respectively. For ART treatments, the clinical pregnancy rate from fresh embryo transfers increased from 45.1% in 2020 (3,119 transfers) to 50.4% in 2021 (8832 transfers), with similar live birth rates, 34.2% vs. 34.4%. Frozen embryo transfers resulted in clinical pregnancy rates of 47.8% in 2020 (2,498 transfers) and 51.9% in 2021 (12,015 transfers), with live birth rates rising from 39.8% to 42.7%. Preimplantation genetic testing cycles resulted in clinical pregnancy rates of 64.2% in 2020 (271 transfers) and 60.8% in 2021 (2,102 transfers), with live birth rates of 53.5% and 48.2%, respectively. Regarding techniques for fertility preservation in females, 11 prepubertal and 61 postpubertal ovarian tissue cryopreservation procedures were reported, alongside 1,346 cycles performed within the same period. In males, 144 post-pubertal testicular tissue, 871 epididymal and 2,480 ejaculated sperm cryopreservations were reported. During the two years, six ovarian tissue transplantations followed by ART were performed, with 96 women using cryopreserved oocytes. In addition, 40 testicular tissue, 298 epididymal, and 238 ejaculated sperm samples were used for ART purposes. This survey provides a comprehensive overview of ART practices in Türkiye for 2020 and 2021, establishing a long-term, national-level analysis while highlighting the challenges posed by the COVID-19 pandemic. The longitudinal analysis established a foundation for future annual reports and offers critical insights into emerging trends over these two years.
- 10 June 2025
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 26 (2) , 109-115
Open AccessIn-depth analysis of the demographic landscape and clinical outcomes of assisted reproductive technologies in Türkiye: a comprehensive survey for the years 2020 and 2021
To investigate patient characteristics and outcomes of assisted reproductive technology (ART) cycles conducted in Türkiye during the coronavirus disease-2019 (COVID-19) pandemic (2020-2021). ART centers in Türkiye were invited to participate in this survey. The questionnaire focused on patient demographics and performance outcomes and was sent to center directors via anonymous Qualtrics™ links. The survey was sent to 167 centers and data were collected from 15 centers in 2020 and 24 centers in 2021. The clinical pregnancy rate from intrauterine insemination (IUI) procedures remained similar, with 15.1% in 2020 (1,245 IUI cycles) and 14.5% in 2021 (2,023 IUI cycles), while successful delivery rates were 12.5% and 11.5%, respectively. For ART treatments, the clinical pregnancy rate from fresh embryo transfers increased from 45.1% in 2020 (3,119 transfers) to 50.4% in 2021 (8832 transfers), with similar live birth rates, 34.2% vs. 34.4%. Frozen embryo transfers resulted in clinical pregnancy rates of 47.8% in 2020 (2,498 transfers) and 51.9% in 2021 (12,015 transfers), with live birth rates rising from 39.8% to 42.7%. Preimplantation genetic testing cycles resulted in clinical pregnancy rates of 64.2% in 2020 (271 transfers) and 60.8% in 2021 (2,102 transfers), with live birth rates of 53.5% and 48.2%, respectively. Regarding techniques for fertility preservation in females, 11 prepubertal and 61 postpubertal ovarian tissue cryopreservation procedures were reported, alongside 1,346 cycles performed within the same period. In males, 144 post-pubertal testicular tissue, 871 epididymal and 2,480 ejaculated sperm cryopreservations were reported. During the two years, six ovarian tissue transplantations followed by ART were performed, with 96 women using cryopreserved oocytes. In addition, 40 testicular tissue, 298 epididymal, and 238 ejaculated sperm samples were used for ART purposes. This survey provides a comprehensive overview of ART practices in Türkiye for 2020 and 2021, establishing a long-term, national-level analysis while highlighting the challenges posed by the COVID-19 pandemic. The longitudinal analysis established a foundation for future annual reports and offers critical insights into emerging trends over these two years.
- Open Access
- 7 March 2024
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 25 (1) , 18-23
Demographic distributions and clinical results of assisted reproduction techniques in Turkey in 2019: a descriptive survey
The aim of this study was to describe characteristics and outcomes of assisted reproductive technology (ART) cycles performed in 2019 in Turkey. One-hundred and sixty-five ART centers in Turkey were invited to submit data. The survey was sent to center directors via e-mail with anonymous links by Qualtrics™. The survey involved questions about their patient characteristics, clinical practices, and outcomes. Forty-one (24.8%) centers responded to e-mails, and data gathered from 25 centers was included in the analyses. In 25 centers, 18,127 fresh or frozen transfers were carried out during the study period, of which 7796 (43.0%) were fresh and the rest were either frozen (45.2%) or embryo transfers (ET) with preimplantation genetic testing (PGT) (11.8%). The live birth rate per ET was as 30.6%, 40.1%, and 50.7% in fresh, frozen and PGT cycles, respectively. A single embryo was transferred in 65.3% of all transfers and singleton live births comprised 86.1% of all deliveries. For cycles with intrauterine insemination, 1407 were started in 2019, and 195 clinical pregnancies, 150 live births with 19 multiple pregnancies occurred. A total of 1513 ART cycles were initiated for foreign patients. Russia (29.6%), Germany (7.4%), Iraq (4.6%), Uzbekistan (3.1%), and Syria (1.4%) were the top five countries with most patients coming to Turkey for ART. The survey results are in parallel with the reports of international institutions and organizations. With repeated editions, the data collected with annual surveys can be used to inform ART practices in the coming years.
- 7 March 2024
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 25 (1) , 18-23
Open AccessDemographic distributions and clinical results of assisted reproduction techniques in Turkey in 2019: a descriptive survey
The aim of this study was to describe characteristics and outcomes of assisted reproductive technology (ART) cycles performed in 2019 in Turkey. One-hundred and sixty-five ART centers in Turkey were invited to submit data. The survey was sent to center directors via e-mail with anonymous links by Qualtrics™. The survey involved questions about their patient characteristics, clinical practices, and outcomes. Forty-one (24.8%) centers responded to e-mails, and data gathered from 25 centers was included in the analyses. In 25 centers, 18,127 fresh or frozen transfers were carried out during the study period, of which 7796 (43.0%) were fresh and the rest were either frozen (45.2%) or embryo transfers (ET) with preimplantation genetic testing (PGT) (11.8%). The live birth rate per ET was as 30.6%, 40.1%, and 50.7% in fresh, frozen and PGT cycles, respectively. A single embryo was transferred in 65.3% of all transfers and singleton live births comprised 86.1% of all deliveries. For cycles with intrauterine insemination, 1407 were started in 2019, and 195 clinical pregnancies, 150 live births with 19 multiple pregnancies occurred. A total of 1513 ART cycles were initiated for foreign patients. Russia (29.6%), Germany (7.4%), Iraq (4.6%), Uzbekistan (3.1%), and Syria (1.4%) were the top five countries with most patients coming to Turkey for ART. The survey results are in parallel with the reports of international institutions and organizations. With repeated editions, the data collected with annual surveys can be used to inform ART practices in the coming years.
- 6 October 2023
- Published by Elsevier in Fertility and Sterility
- Vol. 120 (4) , e46
SEVEN-YEAR FOLLOW-UP OF PLANNED OOCYTE CRYOPRESERVATION OF WOMEN WITH DIMINISHED OVARIAN RESERVE AND/OR ADVANCED AGE: RETURN RATES AND CYCLE OUTCOMES
- 6 October 2023
- Published by Elsevier in Fertility and Sterility
- Vol. 120 (4) , e46
SEVEN-YEAR FOLLOW-UP OF PLANNED OOCYTE CRYOPRESERVATION OF WOMEN WITH DIMINISHED OVARIAN RESERVE AND/OR ADVANCED AGE: RETURN RATES AND CYCLE OUTCOMES
- Open Access
- 17 January 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (3) , 339
Hysteroscopic Endometrial Ablation: From Indications to Instrumentation and Techniques—A Call to Action
The development of minimally invasive techniques has led to the creation of innovative alternatives in cases where traditional methods are not applicable. In modern gynecology, hysteroscopy has become the gold standard for the evaluation and treatment of intrauterine pathology. Endometrial ablation (EA) is a procedure that uses different types of energy to destroy the endometrium and is currently used as an alternative technique in cases of heavy menstrual bleeding when medical treatment has failed and uterine preservation is desired. The aim of this review was to evaluate the feasibility, safety, and clinical outcomes of hysteroscopic EA as an alternative in patients with abnormal uterine bleeding. A detailed computerized search of the literature was performed in the main electronic databases (MEDLINE, EMBASE, Web of Science, PubMed, and Cochrane Library), from 1994 to June 2022, to evaluate the outcomes in patients with abnormal uterine bleeding (AUB) undergoing EA using hysteroscopic and non-hysteroscopic techniques. Only scientific publications in English were included. Twelve articles on the current use of endometrial ablation were included. Data on patient symptoms, tools used for EA, primary outcomes, and adverse events were recorded. EA should be considered an effective and safe approach in the management of patients with abnormal uterine bleeding caused by benign pathology, in whom medical treatment has failed or is contraindicated. Due to the lack of evidence, it would be interesting to determine whether EA would also have a role in the treatment of women with premalignant lesions, avoiding invasive surgical procedures or medical treatment in those patients for whom hysterectomy or the use of hormonal treatment is contraindicated.
- 17 January 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (3) , 339
Open AccessHysteroscopic Endometrial Ablation: From Indications to Instrumentation and Techniques—A Call to Action
The development of minimally invasive techniques has led to the creation of innovative alternatives in cases where traditional methods are not applicable. In modern gynecology, hysteroscopy has become the gold standard for the evaluation and treatment of intrauterine pathology. Endometrial ablation (EA) is a procedure that uses different types of energy to destroy the endometrium and is currently used as an alternative technique in cases of heavy menstrual bleeding when medical treatment has failed and uterine preservation is desired. The aim of this review was to evaluate the feasibility, safety, and clinical outcomes of hysteroscopic EA as an alternative in patients with abnormal uterine bleeding. A detailed computerized search of the literature was performed in the main electronic databases (MEDLINE, EMBASE, Web of Science, PubMed, and Cochrane Library), from 1994 to June 2022, to evaluate the outcomes in patients with abnormal uterine bleeding (AUB) undergoing EA using hysteroscopic and non-hysteroscopic techniques. Only scientific publications in English were included. Twelve articles on the current use of endometrial ablation were included. Data on patient symptoms, tools used for EA, primary outcomes, and adverse events were recorded. EA should be considered an effective and safe approach in the management of patients with abnormal uterine bleeding caused by benign pathology, in whom medical treatment has failed or is contraindicated. Due to the lack of evidence, it would be interesting to determine whether EA would also have a role in the treatment of women with premalignant lesions, avoiding invasive surgical procedures or medical treatment in those patients for whom hysterectomy or the use of hormonal treatment is contraindicated.
- 26 May 2022
- Published by Springer Nature in Reproductive Sciences
- Vol. 29 (10) , 2995-2999
Does Oocyte Retrieval Performance in Mono-follicular Cycles Differ by Physician Experience?
Oocyte pick-up (OPU) is considered as a minor surgical procedure and complications are very rare when performed by trained physicians. However, data on training standards are limited and assessment of proficiency is challenging. The aim of this study was to show the impact of physician experience on OPU performance in mono-follicular in vitro fertilization (IVF) cycles, using two measurable outcome parameters: successful oocyte retrieval and operative time. Senior physicians (n = 6) had over 15 years of experience and novice physicians (n = 4) had at least 30 procedures under supervision. The study population included 226 mono-follicular cycles. Oocyte retrieval was successful in 179 out 226 procedures (79.2%); seniors and novices achieved similar oocyte retrieval rates (74.1%, 43/58 vs 80.9%, 136/168, p = 0.270). The mean duration of the procedure was 513.4 ± 163.1 (126–769) s. It was significantly shorter with a mean difference of − 117.9 s (95% CI: − 164.4 to − 71.3, p = 0.0001, Hedges g = 1.3) for senior physicians when compared to novices (425.8 ± 146.2 versus 543.7 ± 157.9 s). Novices who start performing OPU independently after 30 supervised procedures perform well in collecting the single oocyte grown in mono-follicular cycles; however, the mean duration of the procedure is relatively longer compared to seniors. After initial training period, physicians have few opportunities to compare themselves with their seniors and peers; periodical reassessment of the technique—which should also cover managing the operation time—would help confirm their own practices.
- 26 May 2022
- Published by Springer Nature in Reproductive Sciences
- Vol. 29 (10) , 2995-2999
Does Oocyte Retrieval Performance in Mono-follicular Cycles Differ by Physician Experience?
Oocyte pick-up (OPU) is considered as a minor surgical procedure and complications are very rare when performed by trained physicians. However, data on training standards are limited and assessment of proficiency is challenging. The aim of this study was to show the impact of physician experience on OPU performance in mono-follicular in vitro fertilization (IVF) cycles, using two measurable outcome parameters: successful oocyte retrieval and operative time. Senior physicians (n = 6) had over 15 years of experience and novice physicians (n = 4) had at least 30 procedures under supervision. The study population included 226 mono-follicular cycles. Oocyte retrieval was successful in 179 out 226 procedures (79.2%); seniors and novices achieved similar oocyte retrieval rates (74.1%, 43/58 vs 80.9%, 136/168, p = 0.270). The mean duration of the procedure was 513.4 ± 163.1 (126–769) s. It was significantly shorter with a mean difference of − 117.9 s (95% CI: − 164.4 to − 71.3, p = 0.0001, Hedges g = 1.3) for senior physicians when compared to novices (425.8 ± 146.2 versus 543.7 ± 157.9 s). Novices who start performing OPU independently after 30 supervised procedures perform well in collecting the single oocyte grown in mono-follicular cycles; however, the mean duration of the procedure is relatively longer compared to seniors. After initial training period, physicians have few opportunities to compare themselves with their seniors and peers; periodical reassessment of the technique—which should also cover managing the operation time—would help confirm their own practices.
- Open Access
- 9 May 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (5) , 1176
Abnormal Uterine Bleeding in Perimenopausal Women: The Role of Hysteroscopy and Its Impact on Quality of Life and Sexuality
Abnormal uterine bleeding (AUB) is a frequent symptom in perimenopausal women. It is defined as uterine bleeding in which the duration, frequency, or amount of bleeding is considered excessive and negatively affects the woman’s quality of life (QoL) and psychological well-being. In cases of structural uterine pathology, hysterectomy (usually performed via a minimally invasive approach) offers definitive symptom relief and is associated with long-lasting improvement of QoL and sexuality. However, over the past 30 years, uterus-preserving treatments have been introduced as alternatives to hysterectomy. Hysteroscopic polypectomy, myomectomy, or endometrial resection/endometrial ablation are minimally invasive techniques that can be used as an alternative to hysterectomy to treat AUB due to benign conditions. Although associated with high patient satisfaction and short-term improvement in their QoL, hysteroscopic treatments do not eliminate the risk of AUB recurrence or the need for further intervention. Therefore, considering the impact of different treatment options on QoL and sexuality during preoperative shared decision making could help identify the most appropriate and personalized treatment options for perimenopausal women suffering from AUB.
- 9 May 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (5) , 1176
Open AccessAbnormal Uterine Bleeding in Perimenopausal Women: The Role of Hysteroscopy and Its Impact on Quality of Life and Sexuality
Abnormal uterine bleeding (AUB) is a frequent symptom in perimenopausal women. It is defined as uterine bleeding in which the duration, frequency, or amount of bleeding is considered excessive and negatively affects the woman’s quality of life (QoL) and psychological well-being. In cases of structural uterine pathology, hysterectomy (usually performed via a minimally invasive approach) offers definitive symptom relief and is associated with long-lasting improvement of QoL and sexuality. However, over the past 30 years, uterus-preserving treatments have been introduced as alternatives to hysterectomy. Hysteroscopic polypectomy, myomectomy, or endometrial resection/endometrial ablation are minimally invasive techniques that can be used as an alternative to hysterectomy to treat AUB due to benign conditions. Although associated with high patient satisfaction and short-term improvement in their QoL, hysteroscopic treatments do not eliminate the risk of AUB recurrence or the need for further intervention. Therefore, considering the impact of different treatment options on QoL and sexuality during preoperative shared decision making could help identify the most appropriate and personalized treatment options for perimenopausal women suffering from AUB.
- 1 April 2022
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 44 (4) , 747-754
Dynamic view of assisted reproduction in Turkey from 1996 to 2020
- 1 April 2022
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 44 (4) , 747-754
Dynamic view of assisted reproduction in Turkey from 1996 to 2020
- Open Access
- 15 April 2021
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 48 (2) , 278-282
Oocyte yield of GnRH antagonist cycles scheduled with a short course of estradiol in the early follicular phase
Scheduling in vitro fertilization cycles enables planning oocyte retrieval and embryology procedures in order to suit both patients’ and medical staff’s needs. Current methods to schedule ovarian stimulation cycles are either cumbersome, costly or provide minor flexibility. The aim of this study was to investigate if scheduling gonadotropin releasing hormone (GnRH) antagonist cycles with a short course of estradiol in the early follicular phase affects oocyte yield. Fifty-nine oocyte donors undergoing two GnRH antagonist stimulation cycles within 6 months, one with and one without follicular phase estradiol scheduling (FES), serving as their own control were included in this retrospective cohort study. FES was achieved by giving 6 mg/day estradiol valerate orally from the 2nd–3rd day of menstrual cycle until the desired day of gonadotropin start. Main outcome measures were number of cumulus oocyte complexes and metaphase two oocytes. A total of 118 cycles, 59 FES and 59 unscheduled GnRH antagonist, were included. Median duration of estradiol administration was 3 days in FES cycles. In the FES group, stimulation lasted significantly longer by one day (11 vs 10 days, P = 0.03) and total gonadotropin consumption (2497 vs 2404 IU, P = 0.03) was statistically significantly higher, albeit minimal absolute difference, which is probably short of clinical significance. Numbers of COC (21 vs 20) and metaphase-two oocytes (17 vs 17) were similar between the two groups. In conclusion, FES does not require planning in advance and involves shorter use of estradiol/oral contraceptive tablets and can be advantageous to scheduling with luteal estradiol/oral contraceptive administration.
- 15 April 2021
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 48 (2) , 278-282
Open AccessOocyte yield of GnRH antagonist cycles scheduled with a short course of estradiol in the early follicular phase
Scheduling in vitro fertilization cycles enables planning oocyte retrieval and embryology procedures in order to suit both patients’ and medical staff’s needs. Current methods to schedule ovarian stimulation cycles are either cumbersome, costly or provide minor flexibility. The aim of this study was to investigate if scheduling gonadotropin releasing hormone (GnRH) antagonist cycles with a short course of estradiol in the early follicular phase affects oocyte yield. Fifty-nine oocyte donors undergoing two GnRH antagonist stimulation cycles within 6 months, one with and one without follicular phase estradiol scheduling (FES), serving as their own control were included in this retrospective cohort study. FES was achieved by giving 6 mg/day estradiol valerate orally from the 2nd–3rd day of menstrual cycle until the desired day of gonadotropin start. Main outcome measures were number of cumulus oocyte complexes and metaphase two oocytes. A total of 118 cycles, 59 FES and 59 unscheduled GnRH antagonist, were included. Median duration of estradiol administration was 3 days in FES cycles. In the FES group, stimulation lasted significantly longer by one day (11 vs 10 days, P = 0.03) and total gonadotropin consumption (2497 vs 2404 IU, P = 0.03) was statistically significantly higher, albeit minimal absolute difference, which is probably short of clinical significance. Numbers of COC (21 vs 20) and metaphase-two oocytes (17 vs 17) were similar between the two groups. In conclusion, FES does not require planning in advance and involves shorter use of estradiol/oral contraceptive tablets and can be advantageous to scheduling with luteal estradiol/oral contraceptive administration.
- Open Access
- 18 September 2018
- Published by Galenos Yayinevi in Journal of Turkish Society of Obstetric and Gynecology
- Vol. 15 (3) , 193-199
Use of a gelatin-thrombin hemostatic matrix in obstetrics and gynecological surgery
Gelatin-thrombin matrix (GTM) is a hemostatic sealant consisting of bovine-derived gelatin matrix and human-derived thrombin, combining both mechanical and active mechanisms to achieve hemostasis. It was approved by the Food and Drug Administration in 1999. GTM has been used by several surgical specialties; however, it is a possibly an under-used tool in obstetrics and gynecology. A limited number of studies have been performed on its use during laparoscopic endometrioma excision and myomectomy. It may prove useful in endometrioma excision in reproductive aged women because it is likely to harm ovarian reserve less than electrocautery; however, this conclusion needs to be validated. The only study on GTM use in myomectomy included 50 women randomized into GTM and control groups, and showed decreased blood loss and shorter hospital stays in the GTM group. In gynecologic oncology, it was successfully used to reduce lymphocele cases in a cohort study. GTM has been used successfully in obstetrics in a handful of cases of uncontrolled bleeding from caesarean scar, placental site, ectopic pregnancy, rectovaginal hematoma, and venous plexus over the vaginal vault after emergency postpartum hysterectomy. Risk of viral transmission is a major concern about GTM, yet there are no reports on disease transmission with GTM use to date. Rare but serious adverse effects and complications have been reported such as fatal or near-fatal thromboembolism and small bowel obstruction. Although GTM is mostly a safe product, it is still not free of complications and risks. In conclusion, although routine use of GTM cannot be recommended due to concerns about its safety, cost, and availability, it may prove useful when conventional hemostatic methods such as suturing and electrocauterization fail or are not appropriate.
- 18 September 2018
- Published by Galenos Yayinevi in Journal of Turkish Society of Obstetric and Gynecology
- Vol. 15 (3) , 193-199
Open AccessUse of a gelatin-thrombin hemostatic matrix in obstetrics and gynecological surgery
Gelatin-thrombin matrix (GTM) is a hemostatic sealant consisting of bovine-derived gelatin matrix and human-derived thrombin, combining both mechanical and active mechanisms to achieve hemostasis. It was approved by the Food and Drug Administration in 1999. GTM has been used by several surgical specialties; however, it is a possibly an under-used tool in obstetrics and gynecology. A limited number of studies have been performed on its use during laparoscopic endometrioma excision and myomectomy. It may prove useful in endometrioma excision in reproductive aged women because it is likely to harm ovarian reserve less than electrocautery; however, this conclusion needs to be validated. The only study on GTM use in myomectomy included 50 women randomized into GTM and control groups, and showed decreased blood loss and shorter hospital stays in the GTM group. In gynecologic oncology, it was successfully used to reduce lymphocele cases in a cohort study. GTM has been used successfully in obstetrics in a handful of cases of uncontrolled bleeding from caesarean scar, placental site, ectopic pregnancy, rectovaginal hematoma, and venous plexus over the vaginal vault after emergency postpartum hysterectomy. Risk of viral transmission is a major concern about GTM, yet there are no reports on disease transmission with GTM use to date. Rare but serious adverse effects and complications have been reported such as fatal or near-fatal thromboembolism and small bowel obstruction. Although GTM is mostly a safe product, it is still not free of complications and risks. In conclusion, although routine use of GTM cannot be recommended due to concerns about its safety, cost, and availability, it may prove useful when conventional hemostatic methods such as suturing and electrocauterization fail or are not appropriate.